Adil Khan

Molecular and Cellular Biology

Specializing In:

Tumor immunology

About Adil Khan


Renal Cell Carcinoma (RCC) is the most common kind of kidney cancer accounting for nine out of ten of all kidney cancer cases. While many clinical trials are investigating different modes of therapies for RCC, how these therapies impact tumor immune interactions are poorly understood. My research focuses on characterizing the changes occurring in RCC patient tumors in response to radiation and immune therapy.

My current projects are aimed at:
- Characterizing changes in immune cell populations in RCC tumor microenvironment following radiation treatment using spectral flow cytometry
- Monitoring changes in tumor antigen expression following radiation treatment using xenograft, explant, and cell line models
- Investigating tumor-Immune interaction in RCC post radiation and immune therapy using a novel patient derived tissue fragment model.


Roswell Park Comprehensive Cancer Center

  • HRI Scientist
  • Department of Immunology


Education and Training:

  • 2018 - PhD - Molecular Biology, University of Rochester, Rochester, NY
  • 2011 - MS - Genetics, Bangalore University, Bangalore, Karnataka, India